Last updated: 2026-09-22 16:16:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Atea Pharmaceuticals, Inc. (AVIR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5,53, with a market capitalization of $427,49M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,78 to $6,45. This page covers its latest market performance, valuation, price trends and company information.
$427,49M | |
$5,46 | |
$94,17 | |
$2,46 | |
$5,43 | |
47,48K | |
330,76K | |
-- | |
$6,45 | |
$2,78 | |
-- | |
-- |
Atea Pharmaceuticals, Inc. (AVIR) is currently trading at $5,53 as of 2026-09-22 16:15:00, up 1,84% ($0,10) from the previous close of $5,43
During today's regular trading session, AVIR has traded between $2,46 and $94,17, with a trading volume of 47,48K shares. The current price is near the lower end of today's range.
Over the past seven days, Atea Pharmaceuticals, Inc. (AVIR) moved from $5,31 to $5,53, representing a gain of 4,14% ($0,22).
The stock traded between $5,12 and $5,60 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 368,69 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 74,9%
AVIR is currently trading at $5,53, placing it 74,9% of the way from its 52-week low of $2,78 to its 52-week high of $6,45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 55 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Atea Pharmaceuticals, Inc. (AVIR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.